NeuroSense Therapeutics Ltd. (NRSN) Stock Score, Valuation & Financial Research

NeuroSense Therapeutics Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NRSN

NeuroSense Therapeutics Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 3.85. These figures are a research snapshot, not a buy or sell recommendation.

What NeuroSense Therapeutics Ltd. does

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

NeuroSense Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapeutic candidates for neurodegenerative diseases, relying on capital raises through equity offerings and private placements to fund its ongoing clinical trials and operational activities.

Products and services

  • The company's primary product candidate is PrimeC, an extended-release oral formulation combining ciprofloxacin and celecoxib, currently in clinical development for the treatment of amyotrophic lateral sclerosis (ALS).

Brands and product families

  • PrimeC — Lead therapeutic candidate for the treatment of ALS. Source

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party contract research organizations to conduct its clinical trials and manage data collection. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes unnamed third-party contract manufacturing organizations for the production of its clinical trial drug supplies. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing treatments for ALS and other neurodegenerative diseases, including those with greater financial, technical, and human resources. Source

Business strengths to evaluate

  • Proprietary PrimeC formulation targeting multiple ALS pathology pathways Source

Business risks and research considerations

  • History of operating losses and dependence on future capital raises Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NRSN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.85
Market capitalization:
6.8M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -11.13M
Free cash flow:
USD -7.68M
Cash:
USD 166K
Total debt:
USD 170K
EPS:
USD -8.91

What stands out

  • Free cash flow is USD -7.68M, negative for the stored period.
  • The balance sheet shows USD 166K of cash versus USD 170K of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 4K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NRSN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NRSN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does NRSN's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for NRSN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of NRSN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research NRSN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.